Cargando…

2080: Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review of preclinical studies

OBJECTIVES/SPECIFIC AIMS: To assess the efficacy of exogenous administration of MSCs in animal models of HIE. METHODS/STUDY POPULATION: Adhering to the Systematic Review Protocol for Animal Intervention Studies, a systematic search of English articles was performed using MEDLINE, Web of Science, CIN...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, Alvaro, Archambault, Jamie, McDaniel, Dawn, Hornsby, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798533/
http://dx.doi.org/10.1017/cts.2017.198
_version_ 1783460068525604864
author Moreira, Alvaro
Archambault, Jamie
McDaniel, Dawn
Hornsby, Peter
author_facet Moreira, Alvaro
Archambault, Jamie
McDaniel, Dawn
Hornsby, Peter
author_sort Moreira, Alvaro
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: To assess the efficacy of exogenous administration of MSCs in animal models of HIE. METHODS/STUDY POPULATION: Adhering to the Systematic Review Protocol for Animal Intervention Studies, a systematic search of English articles was performed using MEDLINE, Web of Science, CINAHL, and Google Scholar. Search term items included mesenchymal stem/stromal cell, hypoxic ischemic encephalopathy, asphyxia, cerebral ischemia, and neonatology. We selected randomized and nonrandomized studies that examined in vivo neonatal models of induced HIE. We excluded studies that combined MSCs with an adjunct therapy. Data were collected on study specifics, MSC characteristics, and outcome measurements. The primary outcome was efficacy of MSC treatment, assessed by functional neurologic measures (cognitive, motor, sensory). Risk of bias was assessed using the SYRCLE’s risk of bias tool and we used the ARRIVE guidelines to describe the quality of study reporting. RESULTS/ANTICIPATED RESULTS: A total of 17 preclinical publications focusing on MSC therapy for HIE met our inclusion criteria. Fifteen of the studies (88%) induced HIE in rodents by ligating the common carotid artery followed by a period of hypoxic exposure. Nine (53%) studies derived their MSCs from rodent bone marrow, whereas the other investigators provided xenografts from human bone marrow or umbilical cord-derived MSCs. Range of MSC dose was between 0.25 and 3.5× 106 cells with 71% of the experiments transplanting the MSCs intranasally or intracerebral. Three studies (18%) administered multiple doses. The cylinder rearing test was the most common (73%) sensorimotor functional outcome performed in the first month following the establishment of HIE. All studies demonstrated a reduction in asymmetrical paw preference after receiving MSC therapy. Lesional size was assessed, using neuroimaging or histologic evaluations, and the majority of studies showed a decreased insult following MSC therapy. DISCUSSION/SIGNIFICANCE OF IMPACT: MSC treatment demonstrates improved functional and structural outcomes that are encouraging for future translational studies.
format Online
Article
Text
id pubmed-6798533
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-67985332019-10-28 2080: Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review of preclinical studies Moreira, Alvaro Archambault, Jamie McDaniel, Dawn Hornsby, Peter J Clin Transl Sci Mechanistic Basic to Clinical OBJECTIVES/SPECIFIC AIMS: To assess the efficacy of exogenous administration of MSCs in animal models of HIE. METHODS/STUDY POPULATION: Adhering to the Systematic Review Protocol for Animal Intervention Studies, a systematic search of English articles was performed using MEDLINE, Web of Science, CINAHL, and Google Scholar. Search term items included mesenchymal stem/stromal cell, hypoxic ischemic encephalopathy, asphyxia, cerebral ischemia, and neonatology. We selected randomized and nonrandomized studies that examined in vivo neonatal models of induced HIE. We excluded studies that combined MSCs with an adjunct therapy. Data were collected on study specifics, MSC characteristics, and outcome measurements. The primary outcome was efficacy of MSC treatment, assessed by functional neurologic measures (cognitive, motor, sensory). Risk of bias was assessed using the SYRCLE’s risk of bias tool and we used the ARRIVE guidelines to describe the quality of study reporting. RESULTS/ANTICIPATED RESULTS: A total of 17 preclinical publications focusing on MSC therapy for HIE met our inclusion criteria. Fifteen of the studies (88%) induced HIE in rodents by ligating the common carotid artery followed by a period of hypoxic exposure. Nine (53%) studies derived their MSCs from rodent bone marrow, whereas the other investigators provided xenografts from human bone marrow or umbilical cord-derived MSCs. Range of MSC dose was between 0.25 and 3.5× 106 cells with 71% of the experiments transplanting the MSCs intranasally or intracerebral. Three studies (18%) administered multiple doses. The cylinder rearing test was the most common (73%) sensorimotor functional outcome performed in the first month following the establishment of HIE. All studies demonstrated a reduction in asymmetrical paw preference after receiving MSC therapy. Lesional size was assessed, using neuroimaging or histologic evaluations, and the majority of studies showed a decreased insult following MSC therapy. DISCUSSION/SIGNIFICANCE OF IMPACT: MSC treatment demonstrates improved functional and structural outcomes that are encouraging for future translational studies. Cambridge University Press 2018-05-10 /pmc/articles/PMC6798533/ http://dx.doi.org/10.1017/cts.2017.198 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mechanistic Basic to Clinical
Moreira, Alvaro
Archambault, Jamie
McDaniel, Dawn
Hornsby, Peter
2080: Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review of preclinical studies
title 2080: Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review of preclinical studies
title_full 2080: Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review of preclinical studies
title_fullStr 2080: Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review of preclinical studies
title_full_unstemmed 2080: Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review of preclinical studies
title_short 2080: Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review of preclinical studies
title_sort 2080: therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: a systematic review of preclinical studies
topic Mechanistic Basic to Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798533/
http://dx.doi.org/10.1017/cts.2017.198
work_keys_str_mv AT moreiraalvaro 2080therapeuticpotentialofmesenchymalstromalcellsforhypoxicischemicencephalopathyasystematicreviewofpreclinicalstudies
AT archambaultjamie 2080therapeuticpotentialofmesenchymalstromalcellsforhypoxicischemicencephalopathyasystematicreviewofpreclinicalstudies
AT mcdanieldawn 2080therapeuticpotentialofmesenchymalstromalcellsforhypoxicischemicencephalopathyasystematicreviewofpreclinicalstudies
AT hornsbypeter 2080therapeuticpotentialofmesenchymalstromalcellsforhypoxicischemicencephalopathyasystematicreviewofpreclinicalstudies